Disease activity, pANCA and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis
M Jürgens, R Laubender, F Hartl, M Weidinger, J Wagner, J Seiderer, F Beigel, J Glas, B Göke, T Ochsenkühn, S Brand · Zeitschrift für Gastroenterologie · 2009 · Heft 09
Bibliografische Angaben
Zusammenfassung
Introduction: We analysed efficacy and predictors of response to anti-TNF-α antibody induction therapy using infliximab (IFX) in patients with moderate-to-severe ulcerative colitis (UC) in a large single center cohort. Methods: A total of 90 IFX-treated UC patients was analysed retrospectively. For evaluation of disease activity, the colitis activity index (CAI) was calculated. Genotyping for UC-associated variants in the IL23R gene and the IL2/IL21 region was performed. Results: At week 2 (after the first IFX infusion), 64.1% of IFX-treated patients had clinical response to IFX and 51.3% were in remission. At w…
